Go Deep
Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 16,440 | -78.3 | 8.41 | 0.00 | 969.48 |
| Oct 2026 | 16,593 | -83.2 | 8.25 | 0.00 | 947.58 |
| Oct 2026 | 16,299 | -86.2 | 8.55 | 0.00 | 982.85 |
| Oct 2026 | 16,595 | -83.2 | 8.25 | 0.00 | 945.26 |
| Oct 2026 | 16,363 | -85.6 | 8.48 | 0.00 | 973.76 |
| Oct 2026 | 16,211 | -87.2 | 8.64 | 0.00 | 991.78 |
| Oct 2026 | 16,275 | -86.5 | 8.58 | 0.00 | 981.76 |
| Oct 2026 | 16,323 | -86.0 | 8.53 | 0.00 | 974.11 |
| Oct 2026 | 16,515 | -84.0 | 8.33 | 0.00 | 955.40 |
Fennec Pharmaceuticals Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 17,874,000.0 | 15,108,000.0 | 13,777,000.0 | 12,462,000.0 |
| Net Profit | 1,973,000.0 | 201,000.0 | -4,787,000.0 | -638,000.0 |
| EPS | 0.1 | 0.0 | -0.2 | -0.0 |
Fennec Pharmaceuticals Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 44,642,000.0 | 47,538,000.0 | 21,252,000.0 | 1,535,000.0 | — |
| Net Profit | -9,741,000.0 | -436,000.0 | -16,045,000.0 | -23,714,000.0 | — |
| EPS | -0.3 | 0.0 | -0.6 | -0.9 | — |
Fennec Pharmaceuticals Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 70,551,000.0 | 44,946,000.0 | 26,864,000.0 | 26,939,000.0 | — |
| Total Liabilities | 35,079,000.0 | 50,818,000.0 | 38,486,000.0 | 29,508,000.0 | — |
| Total Equity | 35,472,000.0 | -5,872,000.0 | -11,622,000.0 | -2,569,000.0 | — |
Owes vs Owns
Fennec Pharmaceuticals Inc. owed $0.44 for every $1 it owned in Jun 2026, down from $1.10 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.44× | 0.50× | 1.13× | 1.43× | 1.10× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Fennec Pharmaceuticals Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 52.1%Receivables 32.9%Inventory 2.2%Other assets 12.7%
How it's funded — Dec 2025
Payables 6.6%Other liabilities 43.2%Shareholders' equity 50.3%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 36.8 | 26.6 | 13.3 | 23.8 |
| Receivables | 23.2 | 12.9 | 8.8 | 1.5 |
| Inventory | 1.6 | 1.1 | 2.2 | 0.6 |
| Fixed assets (tangible) | 0.0 | 0.0 | 0.0 | 0.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 9.0 | 4.4 | 2.6 | 1.0 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 0.0 | 19.3 | 30.9 | 24.9 |
| Payables | 4.6 | 3.2 | 3.8 | 2.4 |
| Other liabilities | 30.4 | 28.2 | 3.8 | 2.2 |
| Shareholders' equity | 35.5 | -5.9 | -11.6 | -2.6 |
| Net tangible assets | 35.5 | -5.9 | -11.6 | -2.6 |
Fennec Pharmaceuticals Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -12,473,000.0 | 26,980,000.0 | -17,143,000.0 | -18,058,000.0 | — |
| Financing Activities | 22,627,000.0 | -13,615,000.0 | 6,638,000.0 | 20,732,000.0 | — |